These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 1824559)
1. Surgical adjuvant chemotherapy for breast cancer: a comparison of CMF and CAF regimens. Babar AM J Pak Med Assoc; 1991 Dec; 41(12):293-6. PubMed ID: 1824559 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. Buzzoni R; Bonadonna G; Valagussa P; Zambetti M J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555 [TBL] [Abstract][Full Text] [Related]
3. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326 [TBL] [Abstract][Full Text] [Related]
4. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L; J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260 [TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. Moliterni A; Bonadonna G; Valagussa P; Ferrari L; Zambetti M J Clin Oncol; 1991 Jul; 9(7):1124-30. PubMed ID: 2045854 [TBL] [Abstract][Full Text] [Related]
6. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862 [TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82. Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818 [TBL] [Abstract][Full Text] [Related]
8. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) or cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 69 cases of locally advanced (stage IIIb) breast cancer. Gupta P; Bijlani L; Rath GK; Misra A; Mishra MC; Shukla NK; Kriplani A; Kapur BM Jpn J Surg; 1991 Nov; 21(6):637-42. PubMed ID: 1787609 [TBL] [Abstract][Full Text] [Related]
10. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. Fisher B; Jeong JH; Anderson S; Wolmark N J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89. Ejlertsen B; Mouridsen HT; Jensen MB Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334 [TBL] [Abstract][Full Text] [Related]
12. [Comparison of adjuvant chemotherapy in breast carcinoma with a combination of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and AC (doxorubicin, cyclophosphamide). Initial results of a national cooperative study]. Pribylová O; Petruzelka L; Honová H; Fischer J; Bustová I; Siffnerová H; Kůta M; Miller V; Hacklová M; Machácek J; Kohoutek M; Vodvárka P; Kyselá T; Tajblová J; Suk J; Dorazilová V; Bauer J Sb Lek; 1998; 99(1):25-31. PubMed ID: 9748796 [TBL] [Abstract][Full Text] [Related]
13. [CMF or CAF combination chemotherapy for breast cancer]. Ota J Gan To Kagaku Ryoho; 1996 Dec; 23(14):1886-90. PubMed ID: 8978791 [TBL] [Abstract][Full Text] [Related]
14. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. Gianni L; Baselga J; Eiermann W; Porta VG; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Cussac AL; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez JJ; Mansutti M; Valagussa P; Bonadonna G J Clin Oncol; 2009 May; 27(15):2474-81. PubMed ID: 19332727 [TBL] [Abstract][Full Text] [Related]
15. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG). Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer. Hsieh CI; Liu MC; Cheng SH; Liu TW; Chen CM; Chen CM; Tsou MH; Huang AT Am J Clin Oncol; 2000 Apr; 23(2):122-7. PubMed ID: 10776970 [TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy as an adjuvant treatment in operable breast cancer. Bonadonna G; Brusamolino E; Valagussa P; Rossi A; Brugnatelli L; Brambilla C; De Lena M; Tancini G; Bajetta E; Musumeci R; Veronesi U N Engl J Med; 1976 Feb; 294(8):405-10. PubMed ID: 1246307 [TBL] [Abstract][Full Text] [Related]
18. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J; J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M; J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617 [TBL] [Abstract][Full Text] [Related]
20. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]